Oral Probiotic Containing Streptococcus salivarius K12 and Lactobacillus brevis CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial
Intensive care unit patients with COVID-19 are prone to secondary bacterial pneumonia. Probiotics against oral pathogens might prevent lung colonization and avoid pneumonia. How to cite this article: Lauxen JR, Callegari-Jacques SM, Mombelli AS, <i>et al.</i> Oral Probiotic Containing <i>Streptococcus salivarius</i> K12 and <i>Lactobacillus brevis</i> CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial. J Contemp Dent Pract 2025;26(10):931-937.
Authors
- Fernando Fornari (ORCID: https://orcid.org/0000-0003-0899-329X)
- Sidia M. Callegari‐Jacques (ORCID: https://orcid.org/0000-0002-2489-2539)
- Andrea Mombelli (ORCID: https://orcid.org/0000-0003-3386-8503)
- Tiago Simon
- Jonathan R Lauxen
- Amanda Prando
Institutions
- Universidade Federal do Rio Grande do Sul (BR)
- Universidade de Passo Fundo (BR)
Publication Details
- Journal
- The Journal of Contemporary Dental Practice
- Published
- 2025-11-12
- DOI
- https://doi.org/10.5005/jp-journals-10024-3954
- Primary Topic
- Oral microbiology and periodontitis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universidade Federal do Rio Grande do Sul